Table 1 Patient characteristics
Total cohort | Low MGR (≤ 2.2 mm/month) | High MGR (> 2.2 mm/month) | P value | ||
|---|---|---|---|---|---|
No. of patients | 39 | 23 | 16 | ||
Age(years) | Median(IQR) | 63(42–81) | 63(42–80) | 64(46–81) | 0.41 |
Sex | Male | 29 | 18 | 11 | 0.71 |
Female | 10 | 5 | 5 | ||
Metastatic lesion | Lung | 10 | 3 | 7 | |
Lymph nodes | 7 | 7 | 0 | ||
Bone | 5 | 3 | 2 | ||
others | 17 | 10 | 7 | ||
Previous nephrectomy | Presence | 37 | 21 | 16 | 0.50 |
Absent | 2 | 2 | 0 | ||
Pathological outcome | Clear cell renal cell carcinoma | 35 | 21 | 14 | |
Papillary renal cell carcinoma | 3 | 1 | 2 | ||
Collecting duct carcinoma | 1 | 1 | 0 | ||
IMDC risk | Favorable | 9 | 8 | 1 | 0.01 |
Intermediate | 23 | 14 | 9 | ||
Poor | 7 | 1 | 6 | ||
No. of previous systemic therapies | 2nd Line | 23 | 14 | 9 | 1 |
≥ 3rd Line | 16 | 9 | 7 | ||
Prior treatment | Sunitinib | 12 | 8 | 4 | |
Pazopanib | 7 | 4 | 3 | ||
Axitinib | 5 | 3 | 2 | ||
Everolimus | 5 | 3 | 2 | ||
Avelumab + Axitinib | 3 | 0 | 3 | ||
others | 7 | 5 | 2 | ||
Posterior treatment | Best Supportive Care | 11 | 4 | 7 | |
Axitinib | 9 | 6 | 3 | ||
Sunitinib | 4 | 0 | 4 | ||
Everolimus | 1 | 1 | 0 | ||
others | 14 | 12 | 2 | ||
Baseline NLR | Median(IQR) | 3.26(0.30–14.9) | 2.48(0.30–6.84) | 4.33(1.69–14.9) | 0.046 |
Baseline CRP (mg/L) | Median(IQR) | 0.81(0.04–15.5) | 0.47(0.04–7.54) | 1.35(0.06–15.5) | < 0.01 |
Baseline MGR (mm/month) | Median(IQR) | 1.99(0.11–25.0) | 0.95(0.11–2.15) | 4.46(2.22–25.0) | < 0.01 |